Skip to NavigationSkip to content

Novartis' Xolair scores European approval to treat chronic rhinosinusitis with nasal polyps

Published on 06/08/20 at 11:37am

Novartis has snapped up approval from the European Commission for its anti-immunoglobulin E (IgE) antibody therapy Xolair (omalizumab) for the treatment of severe chronic rhinosinusitis with nasal polyps in adult patients, when used in combination with intranasal corticosteroids (INC).

The decision was reached after evaluating Phase 3 study data which showed that use of Xolair led to improvements in symptoms and quality of life, as well as reduced the size of nasal polyps, as measured by Nasal Polyp Score.

“People with chronic rhinosinusitis with nasal polyps can experience significant quality of life impairment as a result of their symptoms. The symptoms include long-term nasal congestion and blockage, sleep disruption and loss of smell and taste,” remarked Lars Ingemann, Academic Director at the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA). “The EUFOREA patient advisory board welcomes today’s approval, which will provide an additional treatment option to patients with severe chronic rhinosinusitis with nasal polyps.”

This latest authorisation adds to the existing approval of Xolair in the treatment of chronic spontaneous urticaria in more than 90 countries including the European Union, United States and Canada.

Matt Fellows

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches